The multifaceted roles of extracellular vesicles for therapeutic intervention with non-Hodgkin lymphoma

Abstract

Extracellular vesicles (EVs) contribute to the development of cancer in various ways. Non-Hodgkin lymphoma (NHL) is a cancer of mature lymphocytes and the most common hematological malignancy globally. The most common form of NHL, diffuse large B-cell lymphoma (DLBCL), is primarily treated with chemotherapy, autologous stem cell transplantation (ASCT), and/or chimeric antigen receptor T-cell (CAR-T) therapy. With NHL disease progression and its treatment, extracellular vesicles play remarkable roles in influencing outcomes. This finding can be utilized for therapeutic intervention to improve patient outcomes for NHL. This review focuses on the multifaceted roles of EVs with NHL and its potential for guiding patient care.

Keywords

Extracellular vesicles / non-Hodgkin lymphoma (NHL) / diffuse large B-cell lymphoma (DLBCL) / R-CHOP / autologous stem cell transplantation (ASCT) / chimeric antigen receptor T-cell (CAR-T) therapy / biomarkers / microfluidic devices

References

[1] Xu R,Chen M,Greening DW.Extracellular vesicles in cancer - implications for future improvements in cancer care.Nat Rev Clin Oncol2018;15:617-38

[2] Chang W,Antonyak MA. Extracellular vesicles and their roles in cancer progression. In: Robles-flores M, editor. Cancer Cell Signaling. New York: Springer US; 2021. pp. 143-70.

[3] Ye Z,Li G,Lei J.Tissue-derived extracellular vesicles in cancer progression: mechanisms, roles, and potential applications.Cancer Metastasis Rev2024;43:575-95

[4] Crow J,Godwin AK.Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy.Expert Rev Mol Diagn2019;19:1079-88

[5] Trinidad CV,Bantis LE.Reducing ovarian cancer mortality through early detection: approaches using circulating biomarkers.Cancer Prev Res2020;13:241-52 PMCID:PMC7080297

[6] Hinestrosa JP,Lewis JM.Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test.Commun Med2022;2:29 PMCID:PMC9053211

[7] Irmer B,Maas L,Menck K.Extracellular vesicles in liquid biopsies as biomarkers for solid tumors.Cancers2023;15:1307 PMCID:PMC9953862

[8] Yu D,Wang M.Exosomes as a new frontier of cancer liquid biopsy.Mol Cancer2022;21:56 PMCID:PMC8855550

[9] Zhou E,Wu F.Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy.EBioMedicine2021;67:103365 PMCID:PMC8121992

[10] Rayamajhi S,Tetlow AL,Bansal A.Extracellular vesicles as liquid biopsy biomarkers across the cancer journey: from early detection to recurrence.Clin Chem2024;70:206-19

[11] Cheng S,Yan H.Advances in microfluidic extracellular vesicle analysis for cancer diagnostics.Lab Chip2021;21:3219-43 PMCID:PMC8387453

[12] Théry C,Aikawa E.Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines.J Extracell Vesicles2018;7:1535750 PMCID:PMC6322352

[13] Jeppesen DK,Franklin JL.Extracellular vesicles and nanoparticles: emerging complexities.Trends Cell Biol2023;33:667-81 PMCID:PMC10363204

[14] Nowak M,Kołodzińska K,Choromańska A.Extracellular vesicles as drug transporters.Int J Mol Sci2023;24:10267 PMCID:PMC10299356

[15] Hanahan D.Hallmarks of cancer: the next generation.Cell2011;144:646-74

[16] van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles.Nat Rev Mol Cell Biol2018;19:213-28

[17] Decruyenaere P,Vandesompele J.Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review.Exp Hematol Oncol2021;10:13 PMCID:PMC7885416

[18] Ghanam J,Barthel L,Hoyer PF.DNA in extracellular vesicles: from evolution to its current application in health and disease.Cell Biosci2022;12:37 PMCID:PMC8961894

[19] Malkin EZ.Bioactive DNA from extracellular vesicles and particles.Cell Death Dis2020;11:584 PMCID:PMC7385258

[20] Elzanowska J,Costa-Silva B.DNA in extracellular vesicles: biological and clinical aspects.Mol Oncol2021;15:1701-14 PMCID:PMC8169445

[21] Jabalee J,Garnis C.The role of extracellular vesicles in cancer: cargo, function, and therapeutic implications.Cells2018;7:93 PMCID:PMC6115997

[22] Kikuchi S,Prieto-Vila M.Involvement of extracellular vesicles in vascular-related functions in cancer progression and metastasis.Int J Mol Sci2019;20:2584 PMCID:PMC6566766

[23] Bhatta B,Krueger C.Cancer cells shuttle extracellular vesicles containing oncogenic mutant p53 proteins to the tumor microenvironment.Cancers (Basel)2021;13:2985 PMCID:PMC8232660

[24] Putz U,Goh CP,Howitt J.PTEN secretion in exosomes.Methods2015;77-78:157-63

[25] Buzas EI.The roles of extracellular vesicles in the immune system.Nat Rev Immunol2023;23:236-50 PMCID:PMC9361922

[26] Al-Mayah AH,Bowler DA,Goodwin E.Exosome-mediated telomere instability in human breast epithelial cancer cells after X irradiation.Radiat Res2017;187:98-106

[27] Wang Z.The crosstalk of telomere dysfunction and inflammation through cell-free TERRA containing exosomes.RNA Biol2016;13:690-5 PMCID:PMC4993293

[28] Terlecki-Zaniewicz L,Latreille J.Small extracellular vesicles and their miRNA cargo are anti-apoptotic members of the senescence-associated secretory phenotype.Aging2018;10:1103-32 PMCID:PMC5990398

[29] Wang J,Hernot S.Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.Blood2014;124:555-66

[30] Yang L,Wang D,Chen LX.Bladder cancer cell-derived exosomes inhibit tumor cell apoptosis and induce cell proliferation in vitro.Mol Med Rep2013;8:1272-8

[31] Federici C,Caimi S.Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin.PLoS One2014;9:e88193 PMCID:PMC3916404

[32] Ciravolo V,Ghedini GC.Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.J Cell Physiol2012;227:658-67

[33] Samuel P,Furlong F.Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells.Philos Trans R Soc Lond B Biol Sci2018;373:20170065 PMCID:PMC5717443

[34] Ferlizza E,Borrelli F.Extracellular vesicles and epidermal growth factor receptor activation: interplay of drivers in cancer progression.Cancers (Basel)2023;15:2970 PMCID:PMC10252121

[35] Jacobson CA. Non-hodgkin’s lymphoma. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL, editors. Harrison’s Principles of Internal Medicine, 21e. New York: McGraw-Hill; 2022.

[36] NIH: National Cancer Institute. Non-hodgkin lymphoma treatment (PDQ®) – health professional version. Available from: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq [Last accessed on 24 Jun 2024]

[37] Parham P. The immune system. 4th ed. Garland Science: Taylor & Francis Group; 2015. p. 1-532.

[38] Mount Sinai. Non-Hodgkin’s lymphoma. Available from: https://www.mountsinai.org/health-library/report/non-hodgkins-lymphoma [Last accessed on 24 Jun 2024]

[39] Diffuse Large B-Cell. KUMC Panopto pathology slide tours. Available from: https://kumc.hosted.panopto.com/Panopto/Pages/Embed.aspx?pid=54880ca6-5c1e-431f-80a0-ac8d0115fce4&id=b923d9a8-a3de-4f68-b15e-ab3c0164b485 [Last accessed on 24 Jun 2024]

[40] Thandra KC,Saginala K,Barsouk A.Epidemiology of non-Hodgkin’s lymphoma.Med Sci2021;9:5 PMCID:PMC7930980

[41] Navarro-Tableros V,Camussi G.Extracellular vesicles: new players in lymphomas.Int J Mol Sci2018;20:41 PMCID:PMC6337615

[42] Chu Y,Fang X.The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends.Front Oncol2023;13:1059914 PMCID:PMC10272809

[43] NIH: National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer stat facts: non-Hodgkin lymphoma. Available from: https://seer.cancer.gov/statfacts/html/nhl.html [Last accessed on 24 Jun 2024]

[44] Padala SA. Diffuse large B-cell lymphoma. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557796 [Last accessed on 24 Jun 2024]

[45] Basso K.Germinal centres and B cell lymphomagenesis.Nat Rev Immunol2015;15:172-84

[46] Wagener R,Siebert R. Pathogenesis of B-cell lymphoma. In: Abla O, Attarbaschi A, editors. Non-Hodgkin’s Lymphoma in Childhood and Adolescence. Switzerland: Springer, Cham; 2019.

[47] Schmitz R,Huang DW.Genetics and pathogenesis of diffuse large B-cell lymphoma.N Engl J Med2018;378:1396-407 PMCID:PMC6010183

[48] Ofori K,Rai AJ.Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: current state of the art and unmet clinical needs.Br J Clin Pharmacol2021;87:284-94

[49] Wang L,Young KH.New agents and regimens for diffuse large B cell lymphoma.J Hematol Oncol2020;13:175 PMCID:PMC7734862

[50] NIH: National Cancer Institute: Cancer Currents Blog. Should CAR T cells be used earlier in people with non-Hodgkin lymphoma? Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-car-t-cells-belinda-transform-zuma7 [Last accessed on 24 Jun 2024]

[51] Lai CP,Ericsson M.Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter.ACS Nano2014;8:483-94 PMCID:PMC3934350

[52] Ciferri MC,Tasso R.Extracellular vesicles as biomarkers and therapeutic tools: from pre-clinical to clinical applications.Biology2021;10:359 PMCID:PMC8145169

[53] Razvi E.Prognostic vs. predictive biomarkers.Clinical OMICs2014;1:24-5

[54] Oldenhuis CN,Gietema JA.Prognostic versus predictive value of biomarkers in oncology.Eur J Cancer2008;44:946-53

[55] Gutknecht MF,Rothstein TL.B cell extracellular vesicles contain monomeric IgM that binds antigen and enters target cells.iScience2023;26:107526 PMCID:PMC10448175

[56] Zheng D,Li B.The role of exosomes and exosomal microRNA in cardiovascular disease.Front Cell Dev Biol2020;8:616161 PMCID:PMC7835482

[57] O'Brien K,Ughetto S,Breakefield XO.RNA delivery by extracellular vesicles in mammalian cells and its applications.Nat Rev Mol Cell Biol2020;21:585-606 PMCID:PMC7249041

[58] Yu W,Roberts D.Exosome-based liquid biopsies in cancer: opportunities and challenges.Ann Oncol2021;32:466-77 PMCID:PMC8268076

[59] Wei Z,Schinelli S.Coding and noncoding landscape of extracellular RNA released by human glioma stem cells.Nat Commun2017;8:1145 PMCID:PMC5658400

[60] Lai CP,Badr CE.Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters.Nat Commun2015;6:7029 PMCID:PMC4435621

[61] Cao D,Jiang Y.Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.Hematol Oncol2022;40:172-80 PMCID:PMC9299807

[62] Liu J,Hu S.Circulating exosomal MiR-107 restrains tumorigenesis in diffuse large B-cell lymphoma by targeting 14-3-3η.Front Cell Dev Biol2021;9:667800 PMCID:PMC8111223

[63] Xiao XB,Sun DL.Effect of rituximab combined with chemotherapy on the expression of serum exosome miR-451a in patients with diffuse large b-cell lymphoma.Eur Rev Med Pharmacol Sci2019;23:1620-5

[64] Feng Y,Zeng S.Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance.Epigenomics2019;11:35-51

[65] Zare N,Mehrzad V,Kefayat A.Evaluation of exosomal miR-155, let-7g and let-7i levels as a potential noninvasive biomarker among refractory/relapsed patients, responsive patients and patients receiving R-CHOP.Leuk Lymphoma2019;60:1877-89

[66] Yazdanparast S,Keramat S.The roles of exosomal microRNAs in diffuse large B-cell lymphoma: diagnosis, prognosis, clinical application, and biomolecular mechanisms.Front Oncol2022;12:904637 PMCID:PMC9202611

[67] Provencio M,Cantos B.mRNA in exosomas as a liquid biopsy in non-Hodgkin lymphoma: a multicentric study by the Spanish lymphoma oncology group.Oncotarget2017;8:50949-57 PMCID:PMC5584220

[68] Bang YH,Ryu KJ.Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma.J Cancer2022;13:1388-97 PMCID:PMC8965112

[69] Rutherford SC,Li S.Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations.Blood2018;132:e13-23 PMCID:PMC6265635

[70] Chapuy B,Dunford AJ.Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nat Med2018;24:679-90 PMCID:PMC6613387

[71] Hoshino A,Bojmar L.Extracellular vesicle and particle biomarkers define multiple human cancers.Cell2020;182:1044-61.e18 PMCID:PMC7522766

[72] Liu H,Dong Z.Cell-of-Origin subtype prediction of diffuse large B-cell lymphoma using gene expression and proteomic data.Blood2018;132:1712

[73] Bram Ednersson S,Fagman H.Quantitative proteomics in diffuse large B-cell lymphoma patients reveal novel overexpressed proteins and potentially druggable targets in the ABC subtype.Blood2019;134:3967

[74] Carvalho AS,Henriques AFA.Proteomic landscape of extracellular vesicles for diffuse large B-cell lymphoma subtyping.Int J Mol Sci2021;22:11004 PMCID:PMC8536203

[75] Matthiesen R,Henriques A.Extracellular vesicles in diffuse large B cell lymphoma: characterization and diagnostic potential.Int J Mol Sci2022;23:13327 PMCID:PMC9654702

[76] Oksvold MP,Forfang L.Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells.Clin Ther2014;36:847-862.e1

[77] Yao Y,Sun J.Proteomic analysis of exosomes derived from human lymphoma cells.Eur J Med Res2015;20:8 PMCID:PMC4329659

[78] Cheng L.Therapeutically harnessing extracellular vesicles.Nat Rev Drug Discov2022;21:379-99

[79] Caivano A,De Luca L.High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders.Tumour Biol2015;36:9739-52

[80] Cui M,Zhang S,Liao Q.Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis.Front Immunol2021;12:613530 PMCID:PMC8024581

[81] Kurtz DM,Bratman SV.Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.Blood2015;125:3679-87 PMCID:PMC4463733

[82] Merryman RW,Taranto E.Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.Blood Adv2023;7:4748-59 PMCID:PMC10468363

[83] Khodadoust MS,Chen B.B-cell lymphomas present immunoglobulin neoantigens.Blood2019;133:878-81 PMCID:PMC6384186

[84] Couto N,Maia J.IgG⁺ extracellular vesicles measure therapeutic response in advanced pancreatic cancer.Cells2022;11:2800 PMCID:PMC9496671

[85] Aung T,Vogel D.Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.Proc Natl Acad Sci U S A2011;108:15336-41 PMCID:PMC3174603

[86] Melo Garcia L.Harnessing macrophages through the blockage of CD47: implications for acute myeloid leukemia.Cancers2021;13:6258 PMCID:PMC8699809

[87] Schindler C,Matthews C.Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency.PLoS One2019;14:e0214545 PMCID:PMC6440694

[88] Zhu X,Xiao Y.Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells.Cancer Lett2022;536:215668

[89] Ukrainskaya VM,Volkov DV.CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality.Sci Rep2023;13:463 PMCID:PMC9832131

[90] Cox MJ,Sakemura R.Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.Mol Ther2021;29:1529-40 PMCID:PMC8058445

[91] Zhang Y,Huang M.Extracellular vesicles expressing CD19 antigen improve expansion and efficacy of CD19-targeted CAR-T cells.Int J Nanomedicine2023;18:49-63 PMCID:PMC9830716

[92] Huang M,Li D,Wang J.Targeted delivery of IL-12 via CD19-modified extracellular vesicles enhances CAR-T cell efficacy against lymphoma.Blood2023;142:6798

[93] Calvo V.T lymphocyte and CAR-T cell-derived extracellular vesicles and their applications in cancer therapy.Cells2022;11:790 PMCID:PMC8909086

[94] Fu W,Liu S.CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity.Nat Commun2019;10:4355. PMCID:PMC6761190

[95] Yang P,Cai H.The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth.Cell Immunol2021;360:104262.

[96] Aharon A,Bar-Lev TH.Extracellular vesicles derived from chimeric antigen receptor-t cells: a potential therapy for cancer.Hum Gene Ther2021;32:1224-41

[97] Xu Q,Zhao L.Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies.J Control Release2020;326:455-67

[98] Haque S.CD19 chimeric antigen receptor-exosome targets CD19 positive B-lineage acute lymphocytic leukemia and induces cytotoxicity.Cancers2021;13:1401 PMCID:PMC8003442

[99] Marleau AM,Joyce JA.Exosome removal as a therapeutic adjuvant in cancer.J Transl Med2012;10:134 PMCID:PMC3441244

[100] Luan X,Myers I,Yuan H.Engineering exosomes as refined biological nanoplatforms for drug delivery.Acta Pharmacol Sin2017;38:754-63 PMCID:PMC5520184

[101] Ferreira D,Rodrigues LR.New advances in exosome-based targeted drug delivery systems.Crit Rev Oncol Hematol2022;172:103628

[102] Pirisinu M,Zhang DX,Nguyen LT.Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: recent advances, current obstacles, and challenges for clinical translation.Semin Cancer Biol2022;80:340-55

[103] Goh WJ,Zou S,Czarny B.Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy.Int J Nanomedicine2017;12:2759-67 PMCID:PMC5388236

[104] Makita S,Tobinai K.Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Cancer Sci2017;108:1109-18 PMCID:PMC5480083

[105] Neelapu SS,Bartlett NL.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N Engl J Med2017;377:2531-44 PMCID:PMC5882485

[106] Schuster SJ,Tam CS.JULIET InvestigatorsTisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.N Engl J Med2019;380:45-56

[107] Yin Z,Wang X.Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Biomark Res2021;9:58 PMCID:PMC8278776

[108] Sterner RC.CAR-T cell therapy: current limitations and potential strategies.Blood Cancer J2021;11:69 PMCID:PMC8024391

[109] Li M,Abhyankar S.WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1.J Extracell Vesicles2021;10:e12067 PMCID:PMC7869022

[110] Miao L,Ren Z.Reactions related to CAR-T cell therapy.Front Immunol2021;12:663201 PMCID:PMC8113953

[111] Meng X,Fan Q.Characteristics and outcomes of non-Hodgkin's lymphoma patients with leptomeningeal metastases.Int J Clin Oncol2018;23:783-9 PMCID:PMC6097078

[112] Tang XJ,Huang KM.Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy.Oncotarget2015;6:44179-90 PMCID:PMC4792550

[113] Hendrix A,Pinheiro C.Extracellular vesicle analysis.Nat Rev Methods Primers2023;3:56

[114] Steen CB,Esfahani MS.The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma.Cancer Cell2021;39:1422-1437.e10 PMCID:PMC9205168

[115] Bram Ednersson S,Fagman H.Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients.Leuk Lymphoma2021;62:2360-73

[116] Topol EJ.High-performance medicine: the convergence of human and artificial intelligence.Nat Med2019;25:44-56

[117] Rajpurkar P,Banerjee O.AI in health and medicine.Nat Med2022;28:31-8